Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GYRE NASDAQ:ORMP NASDAQ:TECX NASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGYREGyre Therapeutics$6.13+1.3%$6.95$5.44▼$9.42$587.02M1.995,919 shs92,637 shsORMPOramed Pharmaceuticals$3.65+0.3%$3.89$1.98▼$5.01$148.97M1.26195,997 shs217,210 shsTECXTectonic Therapeutic$28.56-1.9%$29.06$14.39▼$36.03$549.09M3.19185,747 shs258,822 shsTLRYTilray Brands$5.17+2.8%$6.01$3.51▼$23.20$586.24M1.883.25 million shs4.91 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGYREGyre Therapeutics+1.32%+10.25%-17.94%-26.41%-27.88%ORMPOramed Pharmaceuticals+0.27%+1.39%-10.76%+7.35%+63.68%TECXTectonic Therapeutic-1.86%+4.12%-1.52%-17.91%+16.67%TLRYTilray Brands+2.78%-3.90%-7.01%-28.39%+26.10%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGYREGyre Therapeutics$6.13+1.3%$6.95$5.44▼$9.42$587.02M1.995,919 shs92,637 shsORMPOramed Pharmaceuticals$3.65+0.3%$3.89$1.98▼$5.01$148.97M1.26195,997 shs217,210 shsTECXTectonic Therapeutic$28.56-1.9%$29.06$14.39▼$36.03$549.09M3.19185,747 shs258,822 shsTLRYTilray Brands$5.17+2.8%$6.01$3.51▼$23.20$586.24M1.883.25 million shs4.91 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGYREGyre Therapeutics+1.32%+10.25%-17.94%-26.41%-27.88%ORMPOramed Pharmaceuticals+0.27%+1.39%-10.76%+7.35%+63.68%TECXTectonic Therapeutic-1.86%+4.12%-1.52%-17.91%+16.67%TLRYTilray Brands+2.78%-3.90%-7.01%-28.39%+26.10%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGYREGyre Therapeutics 2.00Hold$17.00177.32% UpsideORMPOramed Pharmaceuticals 2.00HoldN/AN/ATECXTectonic Therapeutic 3.00Buy$79.40178.01% UpsideTLRYTilray Brands 2.25Hold$11.50122.44% UpsideCurrent Analyst Ratings BreakdownLatest ORMP, GYRE, TLRY, and TECX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026TECXTectonic Therapeutic Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$76.00 ➝ $81.005/13/2026TLRYTilray Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026GYREGyre Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)4/29/2026TLRYTilray Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026TECXTectonic Therapeutic Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/13/2026TECXTectonic Therapeutic Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$75.004/2/2026TLRYTilray Brands ATB Cormark Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$9.50 ➝ $9.004/2/2026TLRYTilray Brands Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$10.003/30/2026TLRYTilray Brands TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $7.003/27/2026ORMPOramed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)3/16/2026GYREGyre Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell(Data available from 6/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGYREGyre Therapeutics$116.59M5.10$0.23 per share27.23$1.48 per share4.14ORMPOramed Pharmaceuticals$2M74.70$0.09 per share40.12$5.02 per share0.73TECXTectonic TherapeuticN/AN/AN/AN/A$13.43 per shareN/ATLRYTilray Brands$821.31M0.73$1.49 per share3.48$14.04 per share0.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGYREGyre Therapeutics$5.03M-$0.09N/AN/AN/A-5.44%3.13%2.67%8/10/2026 (Estimated)ORMPOramed Pharmaceuticals$64.05M$2.591.41N/AN/AN/A-5.37%-4.83%8/14/2026 (Estimated)TECXTectonic Therapeutic-$74.15M-$4.46N/AN/AN/AN/A-32.33%-30.92%8/6/2026 (Estimated)TLRYTilray Brands-$2.19B-$13.65N/AN/AN/A-156.51%-3.31%-2.42%7/27/2026 (Estimated)Latest ORMP, GYRE, TLRY, and TECX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026TECXTectonic Therapeutic-$1.16-$1.34-$0.18-$1.34N/AN/A4/1/2026Q3 2026TLRYTilray Brands-$0.14-$0.24-$0.10-$0.24$201.35 million$206.73 million3/27/2026Q4 2025ORMPOramed Pharmaceuticals-$0.08-$0.06+$0.02$0.24$0.50 millionN/A3/12/2026Q4 2025GYREGyre Therapeutics$0.08$0.04-$0.04-$0.02$36.30 million$37.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGYREGyre TherapeuticsN/AN/AN/AN/AN/AORMPOramed Pharmaceuticals$0.256.85%N/A9.65%N/ATECXTectonic TherapeuticN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGYREGyre TherapeuticsN/A4.644.06ORMPOramed PharmaceuticalsN/A6.456.45TECXTectonic TherapeuticN/A18.5118.51TLRYTilray Brands0.192.791.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGYREGyre Therapeutics23.99%ORMPOramed Pharmaceuticals12.73%TECXTectonic Therapeutic62.63%TLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipGYREGyre Therapeutics9.50%ORMPOramed Pharmaceuticals17.80%TECXTectonic Therapeutic39.80%TLRYTilray Brands0.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGYREGyre Therapeutics4097.03 million87.81 millionNo DataORMPOramed Pharmaceuticals1040.93 million33.64 millionOptionableTECXTectonic Therapeutic12018.87 million11.36 millionN/ATLRYTilray Brands2,842116.55 million115.57 millionOptionableORMP, GYRE, TLRY, and TECX HeadlinesRecent News About These CompaniesTLRY Stock Extends Green Run: Tilray Funds Lyphe Buyout And Debt Reduction With 1.6M New SharesJune 9 at 10:55 PM | stocktwits.comSTilray Reduces Debt Through Private Debt-for-Equity ExchangeJune 9 at 5:51 PM | tipranks.comTilray Brands Inc. stock rises Monday, outperforms marketJune 8 at 11:56 PM | marketwatch.comTilray Brands, Inc. (TLRY) Exceeds Market Returns: Some Facts to ConsiderJune 8 at 11:56 PM | finance.yahoo.comTilray Brands, Inc. (TLRY) Exceeds Market Returns: Some Facts to ConsiderJune 8 at 7:01 PM | zacks.comThe One Market That Could Make or Break Tilray StockJune 8 at 8:51 AM | fool.comIs Tilray's Brewdog Bet Already Backfiring? Collapsing UK Sales Suggest Yes.June 7 at 8:15 PM | fool.comHow The Tilray Brands (TLRY) Story Is Shifting With Rescheduling Hopes And Profit ConcernsJune 6, 2026 | finance.yahoo.comThe Single Biggest Cannabis Catalyst in Years Is Rapidly Approaching: 2 Marijuana Stocks to Buy NowJune 6, 2026 | fool.comCannabis Stocks To Keep An Eye On - June 3rdJune 6, 2026 | americanbankingnews.comWhy Tilray Diversified Strategy Is Drawing Attention?June 6, 2026 | kalkinemedia.comKTLRY Stock Back Into The Limelight – A Look At The Key Developments That Sparked Investor OptimismJune 5, 2026 | stocktwits.comSTop Cannabis Stocks To Add to Your Watchlist - June 2ndJune 5, 2026 | americanbankingnews.comBreckenridge Distillery Introduces Breckenridge Rye Whiskey, A Bold New Expression from the World’s Highest DistilleryJune 4, 2026 | finance.yahoo.comBreckenridge Distillery Introduces Breckenridge Rye Whiskey, A Bold New Expression from the World's Highest DistilleryJune 4, 2026 | globenewswire.comIs This Why Tilray Brands Inc. (TLRY) is one of the Best Sin Stocks to Buy?June 3, 2026 | finance.yahoo.com3 Canadian Marijuana Stocks That Could Help You Make MoneyJune 3, 2026 | marijuanastocks.comMSweetWater Brewing Unveils Atlanta-Wide Soccer Celebration as Global Fans Descend on the City This SummerJune 3, 2026 | finance.yahoo.comSweetWater Brewing Unveils Atlanta-Wide Soccer Celebration as Global Fans Descend on the City This SummerJune 3, 2026 | financialpost.comFSweetWater Brewing Unveils Atlanta-Wide Soccer Celebration as Global Fans Descend on the City This SummerJune 3, 2026 | globenewswire.comTilray Brands (NASDAQ:TLRY) Stock Price Up 1.8% - Here's WhyMay 28, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeORMP, GYRE, TLRY, and TECX Company DescriptionsGyre Therapeutics NASDAQ:GYRE$6.13 +0.08 (+1.32%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$5.94 -0.19 (-3.02%) As of 05:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Oramed Pharmaceuticals NASDAQ:ORMP$3.65 +0.01 (+0.27%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$3.74 +0.10 (+2.60%) As of 06/9/2026 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.Tectonic Therapeutic NASDAQ:TECX$28.56 -0.54 (-1.86%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$26.68 -1.89 (-6.60%) As of 05:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.Tilray Brands NASDAQ:TLRY$5.17 +0.14 (+2.78%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$5.25 +0.08 (+1.55%) As of 05:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Corning Is Paving AI's Future With Glass The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? From Crypto to AI: Insiders Are Trading These 3 Stocks The Case for Intel Over Pure-Play Quantum Firms Has Temu-Owner PDD's Story Changed After Double Miss? Campbell's Soup Stock: Deep Value and a 7% Dividend Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
